Brain magnetic resonance imaging (MRI) is the most effective surveillance tool for the detection of asymptomatic progressive multifocal leukoencephalopathy (PML). However, the optimal frequency for routine MRI surveillance is under-investigated.
Objective:
To understand whether, upon their first MRI appearance, PML lesions present a difference in volume when comparing patients who frequently underwent MRI surveillance (3/4 months) with those who were assessed at longer intervals (6/12 months) and to understand the impact of the volume of lesions on clinical outcome.
Methods:
The data of patients included in the Italian PML cohort were retrospectively analysed. Patients who had all the pre-diagnostic MRI scans available (n = 37) were included. The volume of PML lesion was calculated by manually outlining the PML lesion.
Results:
Compared with patients who underwent MRI examination at least every 4 months, patients who were assessed less frequently had a lesion of significantly higher volume (median: 2567 (883–3583) vs. 664 mm3 (392–963) p = 0.006) and suffered a higher rate of disability (median: 2.25 expanded disability status scale points (–2.5 to 8) vs. 0.5 (–1 to 2.5) p = 0.004).
Conclusion:
The positive clinical outcome of patients undergoing frequent MRI surveillance and the small volume of the PML lesion upon first appearance justify a frequent surveillance using MRI in patients at high risk of PML.
BergerJR.Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord2017; 12: 59–63.
2.
MajorEOYousryTACliffordDB.Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: A decade of lessons learned. Lancet Neurol2018; 17(5): 467–480.
3.
BergerJRAksamitAJCliffordDB, et al. PML diagnostic criteria: Consensus statement from the AAN neuroinfectious disease section. Neurology2013; 80(15): 1430–1438.
4.
ScarpazzaCSignoriAProsperiniL, et al. Early diagnosis of progressive multifocal leukoencephalopathy: Longitudinal lesion evolution. J Neurol Neurosur Ps2019; 90: 261–267.
5.
WijburgMTKleerekooperILissenberg-WitteBI, et al. Association of progressive multifocal leukoencephalopathy lesion volume with JC virus polymerase chain reaction results in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. JAMA Neurol2018; 75: 827–833.
6.
WijburgMTWarnkeCBarkhofF, et al. Performance of PML diagnostic criteria in natalizumab-associated PML: Data from the Dutch-Belgian cohort. J Neurol Neurosur Ps2019; 90: 44–46.
7.
WattjesMPVennegoorAMostertJ, et al. Diagnosis of asymptomatic natalizumab-associated PML: Are we between a rock and a hard place. J Neurol2014; 261(6): 1139–1143.
8.
Dong-SiTRichmanSWattjesMP, et al. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol2014; 1(10): 755–764.
9.
ProsperiniLde RossiNScarpazzaC, et al. Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: Findings from an Italian Independent Registry. PLoS ONE2016; 11(12): e0168376.
10.
Phan-BaRLommersETshibandaL, et al. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosur Ps2012; 83(2): 224–226.
11.
Phan-BaRBelachewSOutteryckO, et al. The earlier, the smaller, the better for natalizumab-associated PML: In MRI vigilance veritas?Neurology2012; 79(10): 1067–1069.
12.
WattjesMPBarkhofF.Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr Opin Neurol2014; 27(3): 260–270.
13.
McGuiganCCranerMGuadagnoJ, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: Recommendations from an expert group. J Neurol Neurosur Ps2016; 87(2): 117–125.
14.
WattjesMPRoviraAMillerD, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients. Nat Rev Neurol2015; 11(10): 597–606.
15.
WattjesMPWarnkeC.High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML – Commentary. Mult Scler2017; 23(6): 770–771.
16.
YapSMMcGuiganC.High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML – Yes. Mult Scler2017; 23(6): 765–767.
17.
EnzingerC.High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML – No. Mult Scler2017; 23(6): 767–770.
18.
MontalbanXGoldRThompsonAJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler2018; 24(2): 96–120.
19.
TraboulseeASimonJHStoneL, et al. Revised recommendations of the consortium of MS centers task force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis. Am J Neuroradiol2016; 37(3): 394–401.
20.
BlairNFBrewBJHalpernJP.Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance. Neurology2012; 78(7): 507–508.
21.
LindaHvon HeijneA.Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy. Front Neurol2013; 4: 11.
22.
Mc GovernEMHennessyMJ. Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab. J Neurol2013; 260(2): 665–667.
23.
AyzenbergILukasCTrampeN, et al. Value of MRI as a surrogate marker for PML in natalizumab long-term therapy. J Neurol2012; 259(8): 1732–1733.
24.
ScarpazzaCProsperiniLDe RossiN, et al. To do or not to do? Plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy. Ann Neurol2017; 82(5): 697–705.
25.
KurtzkeJF.Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology1983; 33(11): 1444–1452.
26.
WijburgMTWitteBIVennegoorA, et al. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. J Neurol Neurosur Ps2016; 87(10): 1138–1145.
27.
HodelJOutteryckODubronC, et al. Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab: Diagnostic precision with MR imaging. Radiology2016; 278(3): 863–872.
28.
WattjesMPVennegoorASteenwijkMD, et al. MRI pattern in asymptomatic natalizumab-associated PML. J Neurol Neurosur Ps2015; 86(7): 793–798.
29.
YousryTAPelletierDCadavidD, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol2012; 72(5): 779–787.
30.
RordenCBrettM.Stereotaxic display of brain lesions. Behav Neurol2000; 12(4): 191–200.
31.
RordenCFridrikssonJKarnathHO.An evaluation of traditional and novel tools for lesion behavior mapping. Neuroimage2009; 44(4): 1355–1362.
32.
CiaramelliEFaggiGScarpazzaC, et al. Subjective recollection independent from multifeatural context retrieval following damage to the posterior parietal cortex. Cortex2017; 91: 114–125.
33.
SellittoMCiaramelliEdi PellegrinoG.Myopic discounting of future rewards after medial orbitofrontal damage in humans. J Neurosci2010; 30(49): 16429–16436.
AustinPC.Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med2009; 28(25): 3083–3107.
36.
ScarpazzaCDe RossiNMoiolaL, et al. The still under-investigated role of cognitive deficits in PML diagnosis. Mult Scler Demyelinating Disord2017; 2: 1.
37.
WarnkeCvon GeldernGMarkwerthP, et al. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol2014; 76(6): 792–801.
38.
CoylePKFoleyJFFoxEJ, et al. Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy. Mult Scler2009; 15(S4): S26–S36.
39.
KapposLBatesDEdanG, et al. Natalizumab treatment for multiple sclerosis: Updated recommendations for patient selection and monitoring. Lancet Neurol2011; 10(8): 745–758.
40.
Dong-SiTGheuensSGangadharanA, et al. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neurovirol2015; 21(6): 637–644.
